ENDRA Life Sciences to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Monday, August 17, 2020 at 4:30 p.m. ET

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ANN ARBOR, MI / ACCESSWIRE / August 5, 2020 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), today announced that its second quarter financial results will be released on Friday, August 14, 2020 after the U.S. financial markets close. Management will host a conference call and webcast on Monday, August 17, 2020 at 4:30 p.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S./Canada Dial-in Number: 844-369-8774
International Dial-in Number: 862-298-0844

Replay Dial-in Number: 877-481-4010
Replay International Dial-in Number: 919-882-2331
Replay Passcode: 36535

A telephone replay will be available August 17, 2020 through 4:30 p.m. ET on August 24, 2020.

A live audio webcast will be available through the Events and Presentations page of the Investors section of the company’s website at www.endrainc.com. A replay of the webcast will be available on the website for 90 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology being developed to visualize tissue like CT or MRI, but at 1/50thof the cost, at the point of patient care. TAEUS is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media Relations Contact:
Denise DiMeglio
(610) 228-2102
denise@gregoryfca.com

Investor Relations Contact:
Joe Hassett
484-686-6600
joeh@gregoryfca.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/600328/ENDRA-Life-Sciences-to-Host-Second-Quarter-2020-Financial-Results-Conference-Call-and-Webcast-on-Monday-August-17-2020-at-430-pm-ET

Staff

Recent Posts

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or…

27 minutes ago

Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month

"Trailblazing Physician and Advocate Receives U.S. Congressional Award for Advancing Healthcare Access and Community Service…

27 minutes ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…

27 minutes ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”,…

27 minutes ago

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by…

27 minutes ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE…

27 minutes ago